Global Standardized Financials

76.73 -1.07(-1.38%)03/06/2026
Bright Minds Biosciences Inc. (DRUG)
Income Statement
(Values in Thousands)
 Q4 2025 (Dec 31, 2025)Q3 2025 (Sep 30, 2025)Q2 2025 (Jun 30, 2025)Q1 2025 (Mar 31, 2025)Q4 2024 (Dec 31, 2024)Q3 2024 (Sep 30, 2024)Q2 2024 (Jun 30, 2024)Q1 2024 (Mar 31, 2024)Q4 2023 (Dec 31, 2023)Q3 2023 (Sep 30, 2023)Q2 2023 (Jun 30, 2023)Q1 2023 (Mar 31, 2023)Q4 2022 (Dec 31, 2022)Q3 2022 (Sep 30, 2022)Q2 2022 (Jun 30, 2022)Q1 2022 (Mar 31, 2022)Q4 2021 (Dec 31, 2021)Q3 2021 (Sep 30, 2021)Q2 2021 (Jun 30, 2021)Q1 2021 (Mar 31, 2021)Q4 2020 (Dec 31, 2020)Q3 2020 (Sep 30, 2020)Q2 2020 (Jun 30, 2020)Q1 2020 (Mar 31, 2020)Q4 2019 (Dec 31, 2019)
Net Income-7,565-4,086-5,243-2,95050-773230-574
Revenue
Cost Of Revenue1716221818
Gross Profit-17-16-22-18-18
Operating Expenses6,9045,6653,2963,3521,625791-254538
Selling General and Administrative Expenses1,089756592676541351321433
Research and Development Expenses5,6614,7842,6922,5631,045416-567105
Other Expenses154124131133824
Cost And Expenses6,9045,6653,2963,3521,625791-236556
Operating Income-6,904-5,665-3,296-3,352-3,299236-556
Interest Income8185304765094615
Income Tax Expense258-0
Income Before Tax-7,565-4,086-5,243-2,95050-773230-574
Earning Per Share Basic-0.97-0.57-0.74-0.420.01-0.170.05-0.13
Earning Per Share Diluted-0.97-0.57-0.74-0.420.01-0.170.05-0.13
weighted Average Shares Outstanding7,7617,1687,0847,0386,1664,4644,4644,464
weighted Average Shares Outstanding (Diluted)7,7617,1687,0847,0386,6424,6494,6494,464
Gross Margin
EBIT Margin
Profit Margin
EBITDA-6,884-5,648-3,280-3,330-1,603-772253-554
Earning Before Tax Margin

Market News ×
Loading news…